Drug Profile
E 6742
Alternative Names: E-6742Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Eisai Inc
- Developer Eisai Co Ltd; Eisai Inc
- Class Antineoplastics
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Systemic lupus erythematosus
- No development reported Autoimmune disorders
- Discontinued Cancer; Neurological disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Japan (PO, Tablet)
- 04 Sep 2023 Eisai completes a phase I/II trial in Systemic lupus erythematosus in Japan (PO) (NCT05278663)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in USA (PO, Capsule)